The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy of metronomic thalimomide and methotrexate for refractory/relapsed non-Hodgkin lymphoma.
Jing-yun Wen
No relevant relationships to disclose
Xiao-kun Ma
No relevant relationships to disclose
Dan-Yun Ruan
No relevant relationships to disclose
Jie Chen
No relevant relationships to disclose
Qu Lin
No relevant relationships to disclose
Min Dong
No relevant relationships to disclose
Xing Li
No relevant relationships to disclose
Xiang-yuan Wu
No relevant relationships to disclose